|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||36.30 - 37.81|
|52 Week Range||28.13 - 39.96|
|Beta (3Y Monthly)||-0.18|
|PE Ratio (TTM)||26.19|
|Forward Dividend & Yield||0.29 (0.77%)|
|1y Target Est||28.03|
Dr. Reddy’s Laboratories Ltd. announced today the launch of Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter store-brand equivalent of Prilosec® OTC Tablets, 20 mg, in the United States market as approved by the U.S.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.
Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing. The case now involves at least 16 companies and 300 drugs, the report said, citing Joseph Nielsen, an assistant attorney general and antitrust investigator in Connecticut, who has been a leader in the probe. Nielsen is quoted as saying, "this is most likely the largest cartel in the history of the United States." The victims were consumers and taxpayers, who have been carrying the high cost of overcharges on common antiboitics, blood-pressure medications, arthritis treatments, anxiety pills and more, said the report. Teva Pharmaceuticals Industries Ltd. ADRs fell 5.7% on the news. Mylan NV was down 4.6%, and Dr. Reddy Labs Ltd was down 3%. Abbott Labs was down 1.4% and Pfizer Inc. was down 1.6%. The S&P 500 was down 1.8% and the Dow Jones Industrial Average was down about 2%.
NEW YORK, Dec. 10, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The stock market has certainly seen its share of volatility in recent months. Sure, the broader S&P 500 (SPX) is down about 8% from Oct. 1, and it has been a pretty wild ride both up and down across the last two months or so. Equally ugly lately has been Apple Inc. (AAPL) which has shed more than 22% since Oct. 1.
Continuous innovation and research in the field of biotechnology and an increasingly aged population in the United States are helping whet appetite for healthcare shares.
Zacks.com highlights: Marcus, Papa Murphy's Holdings, Dr. Reddy's Laboratories, Tesla and Spirit Airlines
Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Chlorthalidone Tablets USP, 25 mg and 50 mg, a therapeutic equivalent generic version of Hygroton Tablets, approved by the U.S.
The U.S. Court of Appeals for the Federal Circuit lifted a preliminary injunction that blocked Dr. Reddy's from selling the generic, saying a lower court judge erred in granting the request. "As a result of today's ruling, Dr. Reddy's will resume its launch activities as soon as permitted," the Hyderabad-based generic drugmaker said https://www.bseindia.com/xml-data/corpfiling/AttachLive/1ee19eb7-226c-43e8-a8e5-7de9b377569a.pdf late on Tuesday. Investors welcomed the news, with shares of Dr. Reddy's reaching their highest in nearly two months - 2,655 rupees.
Dr. Reddy’s Laboratories Ltd. announced today that the United States Court of Appeals for the Federal Circuit issued a decision in favor of Dr.
Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.
Dr. Reddy’s Laboratories Ltd. today announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of Strattera® Capsules in the United States market approved by the U.S.
On a per-share basis, the Hyderabad, India-based company said it had net income of 42 cents. The pharmaceutical posted revenue of $524 million in the period. Doctor Reddy's shares have fallen 13 percent ...
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter and half year ended September 30, 2018 under International Financial Reporting Standards .
NEW YORK, NY / ACCESSWIRE / October 16, 2018 / U.S. markets failed to remain in the green on Monday as a technology sector selloff erased earlier gains. Tech giants Netflix and Apple both dropped more ...
Dr. Reddy’s Laboratories Ltd today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox Capsules in the United States market from the U.S.
Dr. Reddy’s Laboratories Ltd. today announced that it has entered into a definitive agreement for the sale of its API manufacturing business unit located in Jeedimetla, Hyderabad, to Therapiva Private Ltd., an emerging generics pharmaceutical company. This divestiture is being done by way of slump sale and includes all related fixed assets , current assets, current liabilities, and its employees.
Dr. Reddy’s Laboratories Ltd. today announced that it has launched Colesevelam HCl Tablets, USP, a therapeutic equivalent generic version of WELCHOL Tablets in the United States market approved by the U.S.